<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04491422</url>
  </required_header>
  <id_info>
    <org_study_id>REC REF 0105-2020</org_study_id>
    <nct_id>NCT04491422</nct_id>
  </id_info>
  <brief_title>Same-Day PrEP Initiation and Sexual Health for Transgender Women</brief_title>
  <official_title>Same-Day PrEP Initiation and Sexual Health for Transgender Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Medical School (HMS and HSDM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transgender women (trans women; assigned male sex at birth but identify as female) are at&#xD;
      high risk for HIV infection, and are an important, under-researched population in sub-Saharan&#xD;
      Africa. Trans women have a 13 times greater risk of acquiring HIV than adults aged 15-49&#xD;
      years in the general population, and in Africa, trans women have nearly twice the HIV&#xD;
      prevalence (25%) of men who have sex with men [MSM] (14%). Oral pre-exposure prophylaxis&#xD;
      (PrEP) is an effective prevention tool that could change the trajectory of the HIV epidemic&#xD;
      among the 25 million trans women globally, yet its use has been suboptimal in this vulnerable&#xD;
      population. Same-day PrEP initiation is feasible and acceptable and improves retention in&#xD;
      PrEP care in resource-rich settings. Same-day initiation of emtricitabine/tenofovir&#xD;
      alafenamide (F/TAF), a new PrEP regimen, has not to our knowledge previously been evaluated&#xD;
      as PrEP in African trans women. F/TAF is potentially more efficacious and safer than&#xD;
      emtricitabine/tenofovir disoproxil fumarate (F/TDF) as shown in the recent DISCOVER trial.&#xD;
      However, concerns about drug-drug interactions between feminizing hormonal therapy (FHT) and&#xD;
      PrEP are a key potential adherence barrier for trans women. While PrEP drugs do not lower FHT&#xD;
      levels, FHT decreases plasma TFV and (emtricitabine) FTC levels. Little is known about FHT&#xD;
      use among African trans women taking F/TAF or how concerns about F/TAF-FHT interactions may&#xD;
      influence PrEP adherence. Moreover, interventions to support PrEP adherence in this&#xD;
      population are needed. Feedback about PrEP use has been shown to potentially improve PrEP&#xD;
      adherence among MSM but has not been utilized among trans women. Key knowledge gaps include:&#xD;
      1) whether same-day PrEP can be successfully implemented for African trans women, 2) the&#xD;
      impact of drug-level feedback on PrEP adherence, and 3) how use of FHT may influence PrEP&#xD;
      adherence.&#xD;
&#xD;
      To address these questions, this protocol describes a randomized trial to evaluate the&#xD;
      feasibility and acceptability of same day initiation of F/TAF PrEP, evaluate impact of&#xD;
      drug-level feedback on PrEP adherence and characterize PrEP persistence, and in-depth&#xD;
      interviews to explore how self-care interventions for sexual health influence prevention&#xD;
      choices among trans women and their sexual partners. This will be the first clinical trial,&#xD;
      to our knowledge, to evaluate F/TAF as PrEP for HIV-negative trans women in sub-Saharan&#xD;
      Africa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal of this study is to evaluate the feasibility and acceptability of same-day&#xD;
      F/TAF initiation and characterize F/TAF persistence among trans women taking PrEP. This&#xD;
      research will be conducted at the Infectious Diseases Institute, Makerere University in&#xD;
      Kampala, Uganda and consists of 3 complementary aims. In Aims 1 and 2, the investigators will&#xD;
      assess the feasibility and acceptability of same-day F/TAF initiation and characterize PrEP&#xD;
      persistence. In Aim 3, the investigators will use qualitative methods to explore how&#xD;
      self-care interventions for sexual health influence prevention choices among trans women and&#xD;
      their sexual partners. Study subjects will be accrued using respondent driven sampling (RDS)&#xD;
      and enrolled at the study clinic where F/TAF will be initiated same day. Participants will be&#xD;
      randomized in a 1:1 ratio to either the intervention arm (quarterly integrated next steps&#xD;
      counseling [iNSC] using point-of-care [POC] urine tenofovir [TFV] levels) or the control arm&#xD;
      (standard adherence counseling without drug level feedback). In Aim 3, the investigators will&#xD;
      use qualitative methods to explore how self-care interventions for sexual health influence&#xD;
      prevention choices among trans women and their sexual partners. The overall goal will be to&#xD;
      assess whether POC urine testing and iNSC counseling increase PrEP uptake and persistence&#xD;
      over 12 months. This study for trans women is guided by the cardinal ethical principles of&#xD;
      justice, respect for persons and beneficence. The local trans community will be involved in&#xD;
      study design and implementation.&#xD;
&#xD;
      Aim 1 : Evaluate the feasibility and acceptability of same-day F/TAF PrEP initiation among&#xD;
      African trans women.&#xD;
&#xD;
      Approach: The investigators will recruit up to 200 trans women. All study participants who&#xD;
      meet study eligibility criteria will be consented and enrolled at the study clinic.&#xD;
      Randomization will occur through REDCap. Participants will start PrEP on the day of&#xD;
      enrollment and receive F/TAF for 12 months. Free HIV and sexually transmitted infection (STI)&#xD;
      testing and treatment will be provided to all participants.&#xD;
&#xD;
      Aim 2 : Characterize F/TAF persistence and test the impact of drug level feedback among&#xD;
      African trans women taking PrEP.&#xD;
&#xD;
      Approach: Using a factorial design within the Aim 1 study, all F/TAF users will be randomized&#xD;
      to real-time drug level feedback and adherence counseling using a POC urine TFV lateral-flow&#xD;
      immunoassay versus standard counseling alone. Socio-behavioral surveys will assess potential&#xD;
      factors influencing adherence, including gender dysphoria and FHT.&#xD;
&#xD;
      Aim 3 : Explore how self-care interventions for sexual health influence HIV/STI prevention&#xD;
      choices among African trans women and their sexual partners.&#xD;
&#xD;
      Approach: To clarify how same-day PrEP initiation, FHT use and self-collection of samples&#xD;
      (SCS) for STI testing may influence prevention choices, the investigators will conduct&#xD;
      in-depth interviews with participants and their sexual partners to assess perceptions and&#xD;
      experiences with same-day PrEP, real-time drug level feedback, use of FHT, SCS, and how&#xD;
      self-care interventions could empower trans women to engage in prevention services.&#xD;
&#xD;
      Hypothesis: Same-day PrEP initiation will be a feasible and acceptable entryway into PrEP&#xD;
      care among trans women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized in a 1:1 ratio to either quarterly Integrated Next Steps Counseling (iNSC) using point-of-care (POC) urine tenofovir (TFV) levels [intervention arm] or standard adherence counseling without drug level feedback [control arm].</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of same-day initiation of F/TAF as PrEP as measured by participant engagement until the end of study</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion retained on PrEP at months 3, 6, 9 and 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of peer-delivered combination HIV prevention as measured by the System Usability Scale</measure>
    <time_frame>12 months</time_frame>
    <description>System Usability Scale scores range from 0 to 100; higher scores mean better acceptability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adoption of same-day PrEP initiation as measured by structured questionnaires</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion initiating same-day PrEP at enrollment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fidelity to iNSC assessed through audio-recorded drug level feedback counseling sessions</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of research nurses successfully implementing iNSC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PrEP persistence as measured by intracellular tenofovir diphosphate levels in dried blood spots at months 3, 6, 9, 12</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion with tenofovir diphosphate levels &gt;900 fmol per punch</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sexual risk behaviors assessed through structured questionnaires</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion reporting unprotected sex, sexual frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STI incidence assessed through GeneXpert testing</measure>
    <time_frame>12 months</time_frame>
    <description>Neisseria gonorrhoeae and Chlamydia trachomatis incidence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HIV</condition>
  <condition>PrEP</condition>
  <condition>Transgender Women</condition>
  <condition>Sexually Transmitted Diseases, Bacterial</condition>
  <arm_group>
    <arm_group_label>Integrated Next Steps Counseling using poi</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At quarterly visits, intervention arm participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine TFV levels &lt;1000 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard adherence counseling</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control arm participants will receive standard adherence counseling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Integrated Next Steps Counseling with Real-Time Drug Level Feedback</intervention_name>
    <description>Integrated next steps counseling with real-time drug level feedback using point-of-care urine tenofovir testing at quarterly visits</description>
    <arm_group_label>Integrated Next Steps Counseling using poi</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Report male sex assigned at birth but currently identify as female&#xD;
&#xD;
          -  Age â‰¥18, or if 14-17 years, qualification as a mature or emancipated minor due to&#xD;
             having a sexually transmitted infection or cater for own livelihood&#xD;
&#xD;
          -  Report unprotected anal intercourse in the past 6 months&#xD;
&#xD;
          -  Able and willing to provide written informed consent&#xD;
&#xD;
          -  Possess a valid recruitment coupon&#xD;
&#xD;
          -  HIV-uninfected based on negative HIV rapid tests at the enrollment visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently enrolled in a biomedical HIV prevention study&#xD;
&#xD;
          -  Any clinically significant or chronic medical condition that is considered progressive&#xD;
             or in the opinion of the investigator would make the participant unsuitable for the&#xD;
             study, including severe infections requiring treatment such as tuberculosis, alcohol&#xD;
             or drug abuse, or mental illness which precludes provision of informed consent&#xD;
&#xD;
          -  Not planning to remain in the geographic area for the duration of the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Self-identify as transgender women</gender_description>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Mujugira, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Mujugira, PhD</last_name>
    <phone>+256 754 173 225</phone>
    <email>amujugira@idi.co.ug</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvonne Kamara, BA</last_name>
    <phone>+256 777 008 598</phone>
    <email>ykamara@idi.co.ug</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Infectious Diseases Institute Kasangati</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
    <mesh_term>Sexually Transmitted Diseases, Bacterial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

